Orthosomycin Intramammary Therapy for Resistant Mastitis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing antimicrobials used for treating mastitis are ineffective against resistant bacterial strains and face challenges in maintaining antibacterial activity in milk, necessitating the development of new active pharmaceutical ingredients for both treatment and prevention of mastitis.

Innovation Solution

The use of orthosomycin antimicrobial compounds, specifically avilamycin and evernimicin, administered intramammarily via the teat canal, which maintain antibacterial activity against mastitis-causing pathogens like Staphylococcus spp., Streptococcus spp., and Trueperella pyogenes, including resistant strains, with minimal systemic absorption.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antimicrobials are used for mastitis treatment, then existing infections can be treated, but pathogens develop resistance towards the antimicrobials

Engineering Contradiction:

Improveeffectiveness of antimicrobial treatmentVSAvoidbacterial resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by introducing a completely new chemical class of antimicrobials (orthosomycins) with different molecular structures and mechanisms of action compared to conventional antimicrobials. This fundamental parameter change in the antimicrobial agent enables effective treatment of mastitis caused by bacteria resistant to traditional antibiotics, thereby resolving the contradiction between treatment effectiveness and bacterial resistance.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If antimicrobials are administered systemically via blood, then mastitis treatment can be achieved, but antimicrobial activity is reduced in milk

Engineering Contradiction:

Improvesystemic treatment efficacyVSAvoidantimicrobial activity in milk

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent employs intramammary administration as an intermediary delivery method, placing the orthosomycin antimicrobial directly into the mammary gland through the teat canal. This intermediary approach bypasses the limitation of systemic administration where antimicrobial activity is reduced in milk, ensuring high local concentration at the site of infection while maintaining effectiveness in the milk environment.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If intramammary administration is used, then direct treatment of the mammary gland is achieved, but retention of antimicrobial in the teat canal is challenging

Engineering Contradiction:

Improvelocal treatment efficacyVSAvoidretention time in teat canal

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent utilizes a composite formulation consisting of orthosomycin antimicrobial combined with a specific carrier system that enables retention in the teat canal. This composite material approach allows the antimicrobial to be delivered effectively via intramammary administration while maintaining sufficient residence time in the teat canal to ensure therapeutic action, resolving the contradiction between local treatment efficacy and retention duration.

Inventive Principle:

Principle #40Composite materials

Data Source

PatentEP4267146B1An orthosomycin antimicrobial compound for use in methods of treating mastitis

Publication Date: 2025.12.10 INTERVET INT BV

Figure 1

AI summary

This invention relates to methods of treatment and prevention of mastitis in animals by orthosomycin antimicrobial compounds.